Mergers & Acquisitions ·
GSK plc completed its acquisition of Nuvalent, Inc., a Boston-based clinical-stage biopharmaceutical company, for an…
GSKGSK plc
GSK plc completed its acquisition of Nuvalent, Inc., a Boston-based clinical-stage biopharmaceutical company, for an aggregate equity value of approximately $10.6 billion (£8.0 billion). The deal includes the addition of three lung cancer assets to GSK's oncology portfolio, specifically zidesamtinib (NVL-520) and neladalkib (NVL-655), which are under FDA review. GSK's net investment in the transaction was approximately $9.4 billion (£7.1 billion) after accounting for cash acquired. Net non-small cell lung cancer (NSCLC) lung cancer therapies are the primary focus of the acquisition. GSK is a global biopharma company focused on disease prevention and treatment through science and technology.